A Phase 3 interventional study of Lapatinib and Trastuzumab in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 925 sites in 44 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.
Among the 114 studies testing lapatinib in Breast Neoplasms, this one has the largest enrollment, is one of 16 that started in 2007, is one of 18 in phase 3, and was the 43rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 70 · Phase 3 18
First in 2003; this study’s year is marked. 16 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8,381 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 35 across the 114 interventional studies. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
200 studies in Breast Neoplasms by Novartis: 17 open now, 31 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 200 studies in Breast Neoplasms by Novartis, this one has the largest enrollment of the 155 interventional ones that give a count, is one of 7 that started in 2007, is one of 45 in phase 3, and was the 47th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 114 studies testing lapatinib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 200 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone, compared to Trastuzumab alone in the adjuvant treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive early breast cancer.
Treatment allocation was stratified by blocked randomization, with three stratification factors:
The primary objective of this study was to compare disease-free survival (DFS) in subjects with HER2 overexpressing and/or amplified breast cancer randomized to trastuzumab for one year versus lapatinib for one year versus trastuzumab (12 or 18 weeks, according to assigned design) followed by a six week treatment-free interval followed by lapatinib (28 or 34 weeks, according to assigned design) versus trastuzumab in combination with lapatinib for one year (52 weeks).
Secondary objectives included treatment comparisons with respect to overall survival, time to recurrence, time to distant recurrence, safety and tolerability, and incidence of brain metastasis.
Based on the recommendation of the Independent Data Monitoring Committee (IDMC) at the first interim analysis (18-Aug-2011), the Lapatinib alone arm was discontinued prior to primary analysis due to futility. The IDMC also stated that the other three arms (trastuzumab alone, sequential trastuzumab/lapatinib arm and the combination arm) could continued as planned with no changes.
Key Inclusion Criteria:
Key Exclusion Criteria:
Any of the following abnormal laboratory tests immediately prior to randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total). Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total). Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total).
Drug: Lapatinib · Biological: Trastuzumab
Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total). Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total). Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total).
Drug: Lapatinib · Biological: Trastuzumab
Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks. Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total). Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total).
Drug: Lapatinib
Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks. Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total). Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total).
Biological: Trastuzumab
Small molecule inhibitor
Also known as: GW572016
Antibody
Disease-Free Survival (DFS) at the Primary Analysis
Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85, 80 and 75 percent) of participants who had disease free survival for the indicated years.
Time frame: From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years)
Disease-Free Survival (DFS) at the 10-Year Follow-Up
Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85 and 80 percent) of participants who had disease free survival for the indicated years.
Time frame: From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause, assessed up to approximately 10 years
Overall Survival (OS) at the Primary Analysis
Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 97, 96, 95 and 90 percent) of participants who survived for the indicated years.
Time frame: From randomization until death due to any cause (median follow-up of 4.5 years)
Overall Survival (OS) at the 10-Year Follow-Up
Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 95 and 90 percent) of participants who survived for the indicated years.
Time frame: From randomization until death due to any cause, assessed up to approximately 10 years
Analysis of Time to Recurrence (TTR)
Time to Recurrence (TTR) was defined as the the time from randomization to breast cancer recurrence, ignoring second primary cancers (including contralateral breast cancers and non-breast second malignancies) and counting deaths without recurrence as a competing risk.
Time frame: From randomization until the date of the first occurrence of a disease recurrence, assessed up to approximately 10 years
Analysis of Time to Distant Recurrence (TTDR)
Time to Distant Recurrence (TTDR) was defined as the the time from randomization to first distant breast cancer recurrence, ignoring locoregional recurrences and second primary cancers, (including contralateral breast cancers and non-breast second malignancies ) and counting deaths without recurrence as a competing risk.
Time frame: From randomization until the date of the first occurrence of distant recurrence, assessed up to approximately 10 years
Analysis of Time to Central Nervous System (CNS) Recurrence
Time to Central Nervous System (CNS) recurrence was defined as the time from randomization to first CNS recurrence. Both brain metastasis and meningitis carcinomatosa were considered.
Time frame: From randomization until the first central nervous system recurrence, assessed up to approximately 10 years
Cumulative Incidence of Brain Metastases
The cumulative incidence of brain metastases as the first site of breast cancer recurrence among treatment arms was assessed using a hierarchy of primary type and location of first DFS event in cases where more than one event was identified simultaneously. Because diagnostic procedures for different types of recurrence could not be performed on exactly the same day, any diagnoses noted within a two month (60 day) period of the first reported event was considered as identified simultaneously for purposes of defining the type of the first event and the date of event was be regarded as the earliest of the relevant events.
Time frame: From randomization until the date of the first occurrence of a disease recurrence, assessed up to approximately 10 years
This study was conducted in 969 centers in 44 countries worldwide.
| Milestone | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| Started | 2093 | 2091 | 2100 | 2097 |
| Safety population | 2061 | 2076 | 2056 | 2076 |
| Completed | 1132 | 1184 | 1179 | 1192 |
| Not completed | 961 | 907 | 921 | 905 |
| Withdrew: Lost to follow-up | 249 | 216 | 205 | 229 |
| Withdrew: Withdrawal by subject | 333 | 322 | 396 | 295 |
| Withdrew: Patient did not sign icf 12 | 169 | 176 | 139 | 167 |
| Withdrew: Data unavailable due to regulatory issues | 98 | 96 | 85 | 95 |
| Withdrew: Data unavailable due to lapsed ethical consent | 14 | 13 | 14 | 14 |
| Withdrew: Other reasons as defined per protocol | 98 | 84 | 82 | 105 |
Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85, 80 and 75 percent) of participants who had disease free survival for the indicated years.
| Years | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| 95th Percentile | 1.9 | 1.3 | 1.0 | 1.5 |
| 90th Percentile | 3.2 | 2.8 | 1.8 | 2.6 |
| 85th Percentile | 5.1 | 4.8 | 2.8 | 4.2 |
| 80th Percentile | 6.1 | NA | NA | 5.6 |
| 75th Percentile | 6.1 | NA | NA | NA |
Disease-Free Survival (DFS) was defined as the interval between randomization and the date of first occurrence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer or death without recurrence. Only deaths occurring in participants whose clinical follow-up was ongoing at the time of death and who had no recurrence, contralateral breast cancer (CBC) or second primary malignancy (SPM) reported prior to death were considered as death without recurrence. DFS was estimated using the Kaplan Meier method. The percentile data values presented here indicate the percentage (95, 90, 85 and 80 percent) of participants who had disease free survival for the indicated years.
| Years | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| 95th Percentile | 1.89 | 1.27 | — | 1.49 |
| 90th Percentile | 3.21 | 2.80 | — | 2.63 |
| 85th Percentile | 5.92 | 4.85 | — | 4.43 |
| 80th Percentile | 8.99 | 9.18 | — | 7.42 |
Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 97, 96, 95 and 90 percent) of participants who survived for the indicated years.
| Years | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| 99th Percentile | 1.7 | 1.2 | — | 1.7 |
| 98th Percentile | 2.2 | 1.6 | — | 2.1 |
| 97th Percentile | 2.8 | 2.2 | — | 2.6 |
| 96th Percentile | 3.4 | 2.9 | — | 3.0 |
| 95th Percentile | 3.9 | 3.7 | — | 3.6 |
| 90th Percentile | NA | NA | — | 5.9 |
Overall Survival (OS) was defined as the time from randomization until death due to any cause. Participants who had not died were censored at the last date they were known to be alive, or date of withdrawal of consent. OS was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 95 and 90 percent) of participants who survived for the indicated years.
| Years | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| 99th Percentile | 1.68 | 1.17 | — | 1.75 |
| 98th Percentile | 2.19 | 1.60 | — | 2.07 |
| 95th Percentile | 3.92 | 3.52 | — | 3.65 |
| 90th Percentile | 8.31 | 8.49 | — | 6.72 |
Time to Recurrence (TTR) was defined as the the time from randomization to breast cancer recurrence, ignoring second primary cancers (including contralateral breast cancers and non-breast second malignancies) and counting deaths without recurrence as a competing risk.
| Participants | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| Local, regional, or distant recurrence | 243 | 275 | — | 298 |
| Death as a competing risk | 43 | 38 | — | 46 |
| Censored | 1807 | 1778 | — | 1753 |
Time to Distant Recurrence (TTDR) was defined as the the time from randomization to first distant breast cancer recurrence, ignoring locoregional recurrences and second primary cancers, (including contralateral breast cancers and non-breast second malignancies ) and counting deaths without recurrence as a competing risk.
| Participants | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| Distant recurrence | 213 | 238 | — | 250 |
| Death as a competing risk | 45 | 41 | — | 54 |
| Censored | 1835 | 1812 | — | 1793 |
Time to Central Nervous System (CNS) recurrence was defined as the time from randomization to first CNS recurrence. Both brain metastasis and meningitis carcinomatosa were considered.
| Participants | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| CNS recurrence | 91 | 91 | — | 95 |
| Death as a competing risk | 114 | 117 | — | 142 |
| Censored | 1888 | 1883 | — | 1860 |
The cumulative incidence of brain metastases as the first site of breast cancer recurrence among treatment arms was assessed using a hierarchy of primary type and location of first DFS event in cases where more than one event was identified simultaneously. Because diagnostic procedures for different types of recurrence could not be performed on exactly the same day, any diagnoses noted within a two month (60 day) period of the first reported event was considered as identified simultaneously for purposes of defining the type of the first event and the date of event was be regarded as the earliest of the relevant events.
| Participants | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| Cumulative Incidence of Brain Metastases | 50 | 52 | — | 48 |
Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication. On-treatment deaths were collected from first dose of study medication to 30 days after last dose of study medication (on-treatment), up to approximately 56 weeks. Deaths were collected in the post treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to approximately 10 years.
| Participants | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab |
|---|---|---|---|---|
| Pre-treatment deaths | 1 | 2 | 1 | 2 |
| On-treatment deaths | 6 | 5 | 12 | 3 |
| Post-treatment deaths | 189 | 190 | 250 | 228 |
| All deaths | 196 | 197 | 263 | 233 |
Collected over Adverse Events (AEs) were collected from first dose of study medication until the last dose plus 30 days post-treat follow-up, assessed up to approximately 56 weeks. Deaths were recorded from study start date until end of survival follow-up phase (end of study), assessed up to approximately 10 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lapatinib Plus Trastuzumab | 7/2,093 (0.3%) | 379/2,061 (18.4%) | 1,930/2,061 (93.6%) |
| Trastuzumab Followed by Lapatinib | 7/2,091 (0.3%) | 299/2,076 (14.4%) | 1,862/2,076 (89.7%) |
| Lapatinib | 13/2,100 (0.6%) | 394/2,056 (19.2%) | 1,887/2,056 (91.8%) |
| Trastuzumab | 5/2,097 (0.2%) | 251/2,076 (12.1%) | 1,649/2,076 (79.4%) |
| Lapatinib Plus Trastuzumab (Post-Treatment) | 189/2,055 (9.2%) | — | — |
| Trastuzumab Followed by Lapatinib (Post-Treatment) | 190/2,071 (9.2%) | — | — |
| Lapatinib (Post-Treatment) | 250/2,044 (12.2%) | — | — |
| Trastuzumab (Post-Treatment) | 228/2,073 (11%) | — | — |
| Event | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab | Lapatinib Plus Trastuzumab (Post-Treatment) | Trastuzumab Followed by Lapatinib (Post-Treatment) | Lapatinib (Post-Treatment) | Trastuzumab (Post-Treatment) |
|---|---|---|---|---|---|---|---|---|
| HYPERTRANSAMINASAEMIAHepatobiliary disorders | 74/2061 | 55/2076 | 86/2056 | 11/2076 | — | — | — | — |
| DIARRHOEAGastrointestinal disorders | 53/2061 | 6/2076 | 44/2056 | 9/2076 | — | — | — | — |
| NEUTROPENIABlood and lymphatic system disorders | 37/2061 | 21/2076 | 36/2056 | 20/2076 | — | — | — | — |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 24/2061 | 6/2076 | 7/2056 | 19/2076 | — | — | — | — |
| LEUKOPENIABlood and lymphatic system disorders | 20/2061 | 4/2076 | 13/2056 | 7/2076 | — | — | — | — |
| HYPERBILIRUBINAEMIAHepatobiliary disorders | 5/2061 | 12/2076 | 18/2056 | 1/2076 | — | — | — | — |
| PYREXIAGeneral disorders | 11/2061 | 16/2076 | 13/2056 | 5/2076 | — | — | — | — |
| CELLULITISInfections and infestations | 15/2061 | 14/2076 | 7/2056 | 5/2076 | — | — | — | — |
| PNEUMONIAInfections and infestations | 14/2061 | 11/2076 | 9/2056 | 10/2076 | — | — | — | — |
| ANAEMIABlood and lymphatic system disorders | 7/2061 | 6/2076 | 13/2056 | 7/2076 | — | — | — | — |
| Event | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab | Lapatinib Plus Trastuzumab (Post-Treatment) | Trastuzumab Followed by Lapatinib (Post-Treatment) | Lapatinib (Post-Treatment) | Trastuzumab (Post-Treatment) |
|---|---|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 1516/2061 | 1039/2076 | 1278/2056 | 399/2076 | — | — | — | — |
| RASHSkin and subcutaneous tissue disorders | 771/2061 | 685/2076 | 767/2056 | 223/2076 | — | — | — | — |
| FATIGUEGeneral disorders | 511/2061 | 515/2076 | 443/2056 | 439/2076 | — | — | — | — |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 340/2061 | 348/2076 | 320/2056 | 451/2076 | — | — | — | — |
| NAUSEAGastrointestinal disorders | 393/2061 | 393/2076 | 381/2056 | 285/2076 | — | — | — | — |
| HYPERTRANSAMINASAEMIAHepatobiliary disorders | 348/2061 | 378/2076 | 366/2056 | 281/2076 | — | — | — | — |
| NAIL DISORDERSkin and subcutaneous tissue disorders | 359/2061 | 272/2076 | 294/2056 | 220/2076 | — | — | — | — |
| PRURITUSSkin and subcutaneous tissue disorders | 316/2061 | 268/2076 | 334/2056 | 134/2076 | — | — | — | — |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 319/2061 | 213/2076 | 244/2056 | 165/2076 | — | — | — | — |
| DRY SKINSkin and subcutaneous tissue disorders | 262/2061 | 244/2076 | 280/2056 | 86/2076 | — | — | — | — |
| Age, Continuous(years) | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab | Total |
|---|---|---|---|---|---|
| Mean | 50.9 ± 10.23 | 50.8 ± 10.32 | 51.2 ± 10.18 | 51.0 ± 10.25 | 51.0 ± 10.24 |
| Sex: Female, Male(Participants) | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab | Total |
|---|---|---|---|---|---|
| Female | 2091 | 2086 | 2098 | 2097 | 8372 |
| Male | 2 | 5 | 2 | 0 | 9 |
| Race/Ethnicity, Customized(Participants) | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 48 | 45 | 47 | 47 | 187 |
| Asian: Central/South | 107 | 103 | 110 | 109 | 429 |
| Asian: East | 311 | 312 | 299 | 314 | 1236 |
| Asian: Japanese | 33 | 36 | 33 | 43 | 145 |
| Asian: South East | 95 | 92 | 107 | 89 | 383 |
| Black or African American | 38 | 30 | 43 | 25 | 136 |
| Native Hawaiian or Other Pacific | 2 | 4 | 4 | 5 | 15 |
| White: Arabic | 53 | 52 | 62 | 69 | 236 |
| White: Caucasian | 1392 | 1402 | 1372 | 1382 | 5548 |
| Other Race | 14 | 14 | 23 | 14 | 65 |
| Unknown/Missing | 0 | 1 | 0 | 0 | 1 |
| Hormone Receptor (HR) Status(Participants) | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab | Total |
|---|---|---|---|---|---|
| Negative | 890 | 886 | 903 | 897 | 3576 |
| Positive | 1203 | 1205 | 1197 | 1200 | 4805 |
| Timing of Chemotherapy(Participants) | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab | Total |
|---|---|---|---|---|---|
| Sequential | 1155 | 1143 | 1168 | 1147 | 4613 |
| Concurrent | 938 | 948 | 932 | 950 | 3768 |
| Axillary Lymph Node Status(Participants) | Lapatinib Plus Trastuzumab | Trastuzumab Followed by Lapatinib | Lapatinib | Trastuzumab | Total |
|---|---|---|---|---|---|
| Not applicable (neoadjuvant chemotherapy) | 168 | 170 | 167 | 181 | 686 |
| Node negative (no neoadjuvant chemotherapy) | 845 | 842 | 841 | 844 | 3372 |
| 1-3 positive nodes (no neoadjuvant chemotherapy) | 617 | 617 | 620 | 603 | 2457 |
| >= 4 positive nodes (no neoadjuvant chemotherapy) | 463 | 462 | 472 | 469 | 1866 |
Showing the first 100 of 925 sites across 44 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from May 2007 to primary completion in Dec 2013, 78 months.
Results were first posted in Aug 2014, 8 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 78 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lapatinib · Trastuzumab